BI 764122
Alternative Names: BI-764122Latest Information Update: 28 Feb 2023
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Unspecified in Germany (PO, Tablet)
- 09 Jan 2019 Preclinical trials in Unspecified in Germany (PO)
- 09 Jan 2019 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in Germany in January 2019 (NCT03794323; EudraCT2018-003604-39)